Aduhelm is the first drug to be approved by the FDA that claims to treat Alzheimer's disease rather ...
Read moreA dive into the complex and expensive world of gene therapy pricing and access.
Read moreOne year after the first lockdown was announced in the UK we take a brief look at trends and changes...
Read moreBiosimilars could be launching a lot earlier in the UK than the EU thanks to new guidance, improved ...
Read moreAre we one step closer to an EU Health Technology Assessment body. The EESC publish its positive opi...
Read moreThere is a large opportunity many companies are still yet to seize in this area.
Read moreSecuring patient access in specialty products is becoming increasingly challenging due to the comple...
Read moreRemap Consulting has significant expertise in guiding companies through both EUnetHTA / EMA Parallel...
Read moreWithin the last few months, the significant changes proposed to the Italian pricing and reimbursemen...
Read moreTo tackle antibiotic resistance, novel antibiotics are being reserved as later-line therapy for more...
Read more